Venrock Adviser, LLC
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Nov 2026 | $4,495,392,514 | Pooled investment vehicles (100%) |
| Apr 2025 to Mar 2026 | $3,272,084,989 | Pooled investment vehicles (100%) |
| Mar 2025 | $2,891,501,332 | Pooled investment vehicles (100%) |
| Apr 2024 to Feb 2025 | $2,891,501,332 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $2,417,300,965 | Pooled investment vehicles (100%) |
| Apr 2023 | $2,417,300,965 | Pooled investment vehicles (100%) |
In the firm's words
- Value:
In the public markets, the Firm seeks to apply a value-centric approach to identify opportunities to invest in undervalued companies that the Firm believes have potential for substantial appreciation.
- Fundamental active:
The Firm believes that a fundamental research-driven process is a preferred approach to delivering superior long-term returns in the healthcare sector.
- Private markets:
the Funds will also invest in mezzanine financings of private companies
Portfolio style
Measured from the filed 13F common-share book for Sep 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-09-30, active share 98.6%; sector active share 90.1% against the combined 13F book's sector weights.
Over time 27 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+. Stocks and the top 10 weight count issuers: share classes of one company are one stock, and options are left out, so they can differ from the position count and top 10 concentration of GetInstitutionSummary and GetInstitutionPortfolio, which count each listed share class.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
34 common stock positions · as of Sep 30, 2026 · Δ vs Jun 30, 2026Portfolio Trend
Sector Breakdown
Common stock positions · as of Sep 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.6% | $2,050,690,769 |
| Financial Services | 0.4% | $7,353,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc | +5,709,819 | 7,644,072 | $22,167,808 | |
| SVRA | Savara Inc | +4,822,591 | 19,568,534 | $100,973,635 | |
| ACHV | Achieve Life Sciences, Inc. | +2,751,032 | 5,502,064 | $44,511,697 | |
| ERAS | Erasca, Inc. | +2,198,120 | 20,089,932 | $294,518,403 | |
| RLMD | Relmada Therapeutics, Inc. | +600,745 | 7,445,050 | $28,067,838 | |
| CBIO | Crescent Biopharma, Inc. | +158 | 2,133,734 | $31,131,179 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ORIC | Oric Pharmaceuticals, Inc. | −1,375,709 | 2,944,056 | $39,656,434 | |
| KRRO | Korro Bio, Inc. | −566,069 | 443,431 | $4,394,401 | |
| SYRE | Spyre Therapeutics, Inc. | −500,000 | 2,485,448 | $221,279,435 | |
| DNTH | Dianthus Therapeutics, Inc. | −357,980 | 822,020 | $72,378,861 | |
| MAZE | Maze Therapeutics, Inc. | −56,418 | 1,545,616 | $42,009,842 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| KRSA | Korsana Biosciences, Inc. | 4,549,585 | $145,586,720 | |
| ADRX | ADARx Pharmaceuticals, Inc. | 1,625,793 | $32,418,312 | |
| ARVN | Arvinas, Inc. | 1,952,533 | $15,112,605 | |
| ENTX | Entera Bio Ltd. | 5,106,337 | $14,859,440 | |
| TCGX | TCGX Acquisition Corp. | 300,000 | $3,753,000 | |
| RACD | Research Alliance Corp IV | 300,000 | $3,600,000 | |
| INM | InMed Pharmaceuticals Inc. | 133,378 | $0 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| — | 8,493,321 | $1,127,318,496 | ||
| ELVN | Enliven Therapeutics, Inc. | 526,331 | $26,711,298 | |
| HELP | Helus Pharma Inc. | 3,851,654 | $25,459,432 | |
| CTMX | CytomX Therapeutics, Inc. | 4,982,124 | $18,682,965 | |
| RACC | Research Alliance Corp III | 300,000 | $3,210,000 | |
| MTRI | InMed Pharmaceuticals Inc. | 32,685 | $50,661 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 4,148,428 | $345,522,568 | 16.79% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Added | 20,089,932 | $294,518,403 | 14.31% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Reduced | 2,485,448 | $221,279,435 | 10.75% | |
| KRSA |
Korsana Biosciences, Inc.
Healthcare
|
NEW | 4,549,585 | $145,586,720 | 7.07% | |
| SVRA |
Savara Inc
Healthcare
|
Added | 19,568,534 | $100,973,635 | 4.91% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Held | 10,346,926 | $79,360,922 | 3.86% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 3,603,595 | $76,684,501 | 3.73% | |
| DNTH |
Dianthus Therapeutics, Inc.
Healthcare
|
Reduced | 822,020 | $72,378,861 | 3.52% | |
| VRDN |
Viridian Therapeutics, Inc.DE
Healthcare
|
Held | 3,257,917 | $67,080,511 | 3.26% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Held | 3,041,719 | $58,035,998 | 2.82% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 1,642,166 | $52,582,155 | 2.55% | |
| ANL |
Adlai Nortye Group Ltd.
Healthcare
|
Held | 3,212,731 | $51,403,696 | 2.50% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Held | 3,220,364 | $45,246,114 | 2.20% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
Added | 5,502,064 | $44,511,697 | 2.16% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Reduced | 1,545,616 | $42,009,842 | 2.04% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Reduced | 2,944,056 | $39,656,434 | 1.93% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Held | 2,173,913 | $35,021,738 | 1.70% | |
| ADRX |
ADARx Pharmaceuticals, Inc.
Healthcare
|
NEW | 1,625,793 | $32,418,312 | 1.58% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Added | 2,133,734 | $31,131,179 | 1.51% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Added | 7,445,050 | $28,067,838 | 1.36% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Held | 6,434,990 | $26,769,558 | 1.30% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Added | 7,644,072 | $22,167,808 | 1.08% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 1,379,965 | $21,182,462 | 1.03% | |
| SRZN |
Surrozen, Inc.
Healthcare
|
Held | 632,931 | $20,367,719 | 0.99% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
Held | 625,000 | $20,181,250 | 0.98% | |
| ARVN |
Arvinas, Inc.
Healthcare
|
NEW | 1,952,533 | $15,112,605 | 0.73% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 8,695,652 | $14,869,564 | 0.72% | |
| ENTX |
Entera Bio Ltd.
Healthcare
|
NEW | 5,106,337 | $14,859,440 | 0.72% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
Held | 2,043,596 | $14,550,403 | 0.71% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Held | 500,000 | $12,765,000 | 0.62% | |
| KRRO |
Korro Bio, Inc.
Healthcare
|
Reduced | 443,431 | $4,394,401 | 0.21% | |
| TCGX |
TCGX Acquisition Corp.
Financial Services
|
NEW | 300,000 | $3,753,000 | 0.18% | |
| RACD |
Research Alliance Corp IV
Financial Services
|
NEW | 300,000 | $3,600,000 | 0.17% | |
| INM |
InMed Pharmaceuticals Inc.
Healthcare
|
NEW | 133,378 | $0 | 0.00% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.